We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Arbutus Biopharma Corporation | NASDAQ:ABUS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.37% | 2.73 | 2.70 | 2.95 | 2.78 | 2.70 | 2.73 | 406,742 | 01:00:00 |
British Columbia, Canada
(State or Other Jurisdiction of
Incorporation or Organization)
|
001-34949
(Commission File Number)
|
98-0597776
(I.R.S. Employer
Identification No.)
|
|
|
|
701 Veterans Circle
Warminster, Pennsylvania
(Address of Principal Executive Offices)
|
|
18974
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Shares, no par value
|
ABUS
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Proposal 1.
|
The election of seven director nominees named in the Proxy Statement/Circular to serve until the 2020 Annual General Meeting of Shareholders or until their qualified successors have been duly elected or appointed.
|
Nominee
|
|
Votes For
|
|
%
For |
|
Votes
Withheld |
|
%
Withheld |
|
Broker Non-
Votes |
|
Frank Torti, M.D.
|
|
36,179,093
|
|
97.95
|
|
757,567
|
|
2.05
|
|
9,708,472
|
|
Mark J. Murray, Ph.D.
|
|
34,798,586
|
|
94.21
|
|
2,138,074
|
|
5.79
|
|
9,708,472
|
|
Daniel Burgess
|
|
36,537,599
|
|
98.92
|
|
399,061
|
|
1.08
|
|
9,708,472
|
|
Richard C. Henriques
|
|
34,777,759
|
|
94.16
|
|
2,158,901
|
|
5.84
|
|
9,708,472
|
|
Keith Manchester, M.D.
|
|
36,202,934
|
|
98.01
|
|
733,726
|
|
1.99
|
|
9,708,472
|
|
Myrtle S. Potter
|
|
34,093,669
|
|
92.30
|
|
2,842,991
|
|
7.70
|
|
9,708,472
|
|
James Meyers
|
|
36,574,900
|
|
99.02
|
|
361,760
|
|
0.98
|
|
9,708,472
|
|
Proposal 2.
|
The approval of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019:
|
Votes For
|
|
%
For |
|
Votes
Withheld |
|
%
Withheld |
|
Abstain
|
|
Broker Non-Votes
|
46,575,648
|
|
99.85
|
|
69,484
|
|
0.15
|
|
487,172
|
|
0
|
1 Year Arbutus Biopharma Chart |
1 Month Arbutus Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions